Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy

BACKGROUND: Unresectable locally advanced pancreatic cancer (LAPC) is generally managed with chemotherapy or chemoradiotherapy, but prognosis is poor with a median survival of ∼13 months (or up to 19 months in some studies). We assessed a novel brachytherapy device, using phosphorous-32 ((32)P) micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, P.J., Wasan, H.S., Croagh, D., Nikfarjam, M., Nguyen, N., Aghmesheh, M., Nagrial, A.M., Bartholomeusz, D., Hendlisz, A., Ajithkumar, T., Iwuji, C., Wilson, N.E., Turner, D.M., James, D.C., Young, E., Harris, M.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717429/
https://www.ncbi.nlm.nih.gov/pubmed/34953400
http://dx.doi.org/10.1016/j.esmoop.2021.100356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717429/
https://www.ncbi.nlm.nih.gov/pubmed/34953400
http://dx.doi.org/10.1016/j.esmoop.2021.100356

Ejemplares similares